Literature DB >> 28367881

Epidemiological Characteristics and Clinical Treatment Outcome of Typhoid Fever in Ningbo, China, 2005-2014: Pulsed-Field Gel Electorophoresis Results Revealing Great Proportion of Common Transmission Sources.

Qifa Song1, Yuanbin Yang1, Wenping Lin1, Bo Yi1, Guozhang Xu1.   

Abstract

We aimed to describe the molecular epidemiological characteristics and clinical treatment outcome of typhoid fever in Ningbo, China during 2005-2014. Eighty-eight Salmonella Typhi isolates were obtained from 307 hospitalized patients. Three prevalent pulsed-field gel electrophoresis (PFGE) patterns of 54 isolates from 3 outbreaks were identified. Overall, there were 64 (72.7%) isolates from clustered cases and 24 (27.3%) isolates from sporadic cases. Resistance to nalidixic acid (NAL) (n = 47; 53.4%) and ampicillin (AMP) (n = 40; 45.4%) and rare resistance to tetracycline (TET) (n = 2; 2.3%) and gentamicin (GEN) (n = 2; 2.3%) were observed. No isolates resistant to cefotaxime (CTX), chloramphenicol (CL), ciprofloxacin (CIP), and trimethoprim-sulfamethoxazole (SXT) were found. The occurrence of reduced sensitivity to CIP was 52.3% (n = 46). The medians of fever clearance time in cases with and without complications were 7 (interquartile range (IQR): 4-10) and 5 (IQR: 3-7) days (P = 0.001), respectively, when patients were treated with CIP or levofloxacin (LEV) and/or third-generation cephalosporins (CEP). Rates of serious complications were at low levels: peritonitis (2.3%), intestinal hemorrhage (6.8%), and intestinal perforation (1.1%). The present study revealed a long-term clustering trend with respect to PFGE patterns, occasional outbreaks, and the rapid spread of AMP resistance and decreased CIP susceptibility among S. Typhi isolates in recent years.

Entities:  

Keywords:  Salmonella enterica serotype typhi; antimicrobial resistance; clinical treatment outcome; pulsed-field gel electrophoresis (PFGE)

Mesh:

Substances:

Year:  2017        PMID: 28367881     DOI: 10.7883/yoken.JJID.2016.434

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  5 in total

1.  Overview of the development of quinolone resistance in Salmonella species in China, 2005-2016.

Authors:  Qifa Song; Zhaojun Xu; Hong Gao; Danyang Zhang
Journal:  Infect Drug Resist       Date:  2018-02-26       Impact factor: 4.003

2.  Expansion of Salmonella Typhi clonal lineages with ampicillin resistance and reduced ciprofloxacin susceptibility in Eastern China.

Authors:  Dingfeng Lv; Danyang Zhang; Qifa Song
Journal:  Infect Drug Resist       Date:  2019-07-22       Impact factor: 4.003

3.  Occurrence of Typhoid Fever Complications and Their Relation to Duration of Illness Preceding Hospitalization: A Systematic Literature Review and Meta-analysis.

Authors:  Ligia María Cruz Espinoza; Ellen McCreedy; Marianne Holm; Justin Im; Ondari D Mogeni; Prerana Parajulee; Ursula Panzner; Se Eun Park; Trevor Toy; Andrea Haselbeck; Hye Jin Seo; Hyon Jin Jeon; Jong-Hoon Kim; Soo Young Kwon; Jerome H Kim; Christopher M Parry; Florian Marks
Journal:  Clin Infect Dis       Date:  2019-10-30       Impact factor: 9.079

4.  Ileal Perforation and Enteric Fever: Implications for Burden of Disease Estimation.

Authors:  Swathi Krishna Njarekkattuvalappil; Maria Thomas; Arti Kapil; Karnika Saigal; Pallab Ray; Shalini Anandan; Savitha Nagaraj; Jayanthi Shastri; Sulochana Putli Bai Perumal; Dasaratha Ramaiah Jinka; Shajin Thankaraj; Vijayanand Ismavel; Pradeep Zachariah; Ashita Singh; Madhu Gupta; Sheena Evelyn Ebenezer; Mathew Santosh Thomas; Dhruva Ghosh; Kamal Kataria; Mamta Senger; Sundaram Balasubramanian; Gagandeep Kang; Jacob John
Journal:  J Infect Dis       Date:  2021-11-23       Impact factor: 5.226

5.  Genomic Investigation Reveals a Community Typhoid Outbreak Caused by Contaminated Drinking Water in China, 2016.

Authors:  Bing Hu; Peibin Hou; Lin Teng; Song Miao; Lijiang Zhao; Shengxiang Ji; Tao Li; Corinna Kehrenberg; Dianmin Kang; Min Yue
Journal:  Front Med (Lausanne)       Date:  2022-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.